Patient Protection and Affordable Care Act implementation.
FDA approval process/510(k) legislation.
Medical device tax legislation.
Duration: June 1, 2007
to
January 19, 2014
General Issues: Health Issues , Taxation/Internal Revenue Code , Budget/Appropriations , Pharmacy , Copyright/Patent/Trademark , Medicare/Medicaid , Medical/Disease Research/Clinical Labs
Spending: about $1,370,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2007: House of Representatives, U.S. Senate, Executive Office of the President (EOP), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Office of Science & Technology Policy (OSTP), Health & Human Services - Dept of (HHS), White House Office
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Anne Marie Polak Leg. Correspondent for Cong. Mike Ferguson
Legislative Correspondent, Rep. Mike Ferguson
Asst. Scheduler/Scheduler, Rep. Dick Armey
Briefing Book Coordinator/Sec'y of Labor, DOL
Leg. Correspondent for Rep. Mike Ferguson
Paul Brathwaite Exec Dir, Congressional Black Caucus 22 Mem
Executive Director, Cong. Black Caucus
CoS/Deputy Asst. Secy, DOL/Empl't Stds. Adm.
Special Asst. to the Secretary, Dept. of Labor
Intern, Rep. Michael N. Castle
Exec. Dir., Congressional Black Caucus
Andrew Kauders Sr. Adv. Sen. Menendez; ED, House Demo Caucus
Aranthan Jones Policy Director, Rep James Clyburn
Chief of Staff Rep. Andre Carson; Policy Adv.
Health Policy Dir., Congressional Black Caucus
Aranthan Jones II Policy Director, Rep James Clyburn
Chief of Staff Rep. Andre Carson; Policy Adv.
Health Policy Dir., Congressional Black Caucus
Stephen Northrup Health Policy Director, Sen. Michael Enzi
Nora Connors Leg. Assistant, Sen. Dianne Feinstein
Andrew Lewin Leg. Asst./Leg. Director, Rep. Dennis Moore
Leg. Asst./Leg. Director, Rep. Max Sandlin
Donnice Turner Legislative Assistant, Sen. Richard Durbin
Legislative Director, Rep. David Scott
LA/Senior Staff Counsel, Sen. Max Cleland
LA / Senior Staff Counsel, Sen. Max Cleland
Tom Sparkman Health Policy Intern, Senate HELP Committee
Dale Oak Budget Preparation Specialist, OMB
Staff Assistant, House Appropriations Committee
Staff Dir. House Appropriations Subcommittee
Elizabeth Morra Sen. Thad Cochran, conference & personal staff
House Appropriations Committee
John Scofield Comm. Dir., House Approps. Committee
David Morrison Staff Dir., House Approps., Defense Subcommittee
Donni Turner Legislative Assistant, Senator Richard Durbin
Senior Staff Counsel, Sen. Max Cleland
Legislative Director, Rep. David Scott
Walter Pryor Legislative Director, Senator Mark Pryor
Lantie Slenzak Leg. Dir. Rep. Gene Green
Legislative Director, Rep. Gene Green
Leg. Dir. for Rep. Gene Green
Anthony Podesta n/a
Sharon Cohen n/a
Daniele Baierlein n/a
Elizabeth Sage n/a
Thomas Sparkman n/a
Cristina Antelo n/a
Steve Northrup n/a
Randall Gerard n/a
Kimberley Fritts n/a
Michelle Tessier n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2014
PODESTA GROUP, INC. terminated an engagement in which they represented Covidien on April 21, 2014.
Original Filing: 300647112.xml
Lobbying Issues
Patient Protection and Affordable Care Act implementation.
FDA approval process/510(k) legislation.
Medical device tax legislation.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2013
In Q4, PODESTA GROUP, INC. lobbied for Covidien , earning $60,000. The report was filed on Jan. 22, 2014.
Original Filing: 300628403.xml
Lobbying Issues
Patient Protection and Affordable Care Act implementation.
FDA approval process/510(k) legislation.
Medical device tax legislation.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
International taxation on direct foreign investment.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Health care budget issues and appropriations.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, PODESTA GROUP, INC. lobbied for Covidien , earning $60,000. The report was filed on Oct. 21, 2013.
Original Filing: 300608089.xml
Lobbying Issues
Patient Protection and Affordable Care Act implementation.
Issues related to nuclear medicine and isotopes production.
FDA approval process/510(k) legislation.
Medical device tax legislation.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
International taxation on direct foreign investment.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Health care budget issues and appropriations.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, PODESTA GROUP, INC. lobbied for Covidien , earning $60,000. The report was filed on July 22, 2013.
Original Filing: 300583362.xml
Lobbying Issues
Issues involving controlled substances and pain and addiction drugs.
Issues related to acetaminophen.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patient Protection and Affordable Care Act implementation.
Issues related to nuclear medicine and isotopes production.
FDA approval process/510(k) legislation.
Medical device tax legislation.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
International taxation on direct foreign investment.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Health care budget issues and appropriations.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, PODESTA GROUP, INC. lobbied for Covidien , earning $60,000. The report was filed on April 22, 2013.
Original Filing: 300562336.xml
Lobbying Issues
Issues involving controlled substances and pain and addiction drugs.
Issues related to acetaminophen.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patient Protection and Affordable Care Act implementation.
Issues related to nuclear medicine and isotopes production.
FDA approval process/510(k) legislation.
Medical device tax legislation.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
International taxation on direct foreign investment.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Health care budget issues and appropriations.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, PODESTA GROUP, INC. lobbied for Covidien , earning $60,000. The report was filed on Jan. 22, 2013.
Original Filing: 300542747.xml
Lobbying Issues
Issues involving controlled substances and pain and addiction drugs.
Issues related to acetaminophen.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patient Protection and Affordable Care Act implementation.
S. 99, American Medical Isotopes Production Act of 2011; issues related to nuclear medicine.
FDA approval process/510(k).
Medical device tax.H.R. 3209, Premarket Predictability Act.
H.R. 3203 / S. 1943, Novel Device Regulatory Relief Act.
H.R. 3230, Keeping America Competitive through Harmonization Act.
H.R. 3205, FDA Renewing Efficiency from Outside Review Management Act.
H.R. 3211, Humanitarian Device Reform Act.
H.R. 3208, Patients Come First Act.
H.R. 3206, Cultivating Scientific Experts to Foster Innovation Act.
H.R. 3214, Food and Drug Administration Mission Reform Act.
H.R. 3207, Modernizing Laboratory Test Standards for Patients Act.
H.R. 3204, Guidance Accountability and Transparency Act.
S. 1700, The Medical Device Regulatory Improvement Act.
S. 1865, The Patient Access to Medical Innovation Act.
S. 1972, A bill to amend the Food and Drug Administrations mission.
S. 1995, A bill to enhance Food and Drug Administration oversight of medical device recalls, to provide for the conditional clearance of certain medical devices, and for other purposes.
CMS coverage for transcutaneous electrical nerve stimulation for lower back pain
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
International taxation on direct foreign investment.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
FY 2013 President's Budget
H. Con. Res. 112, Establishing the budget for the United States Government for fiscal year 2013 and setting forth appropriate budgetary levels for fiscal years 2014 through 2022.
Health care budget issues, fiscal year 2013 appropriations.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, PODESTA GROUP, INC. lobbied for Covidien , earning $60,000. The report was filed on Oct. 22, 2012.
Original Filing: 300518427.xml
Lobbying Issues
Issues involving controlled substances and pain and addiction drugs.
Issues related to acetaminophen.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patient Protection and Affordable Care Act implementation.
S. 99, American Medical Isotopes Production Act of 2011; issues related to nuclear medicine.
FDA approval process/510(k).
Medical device tax.H.R. 3209, Premarket Predictability Act.
H.R. 3203 / S. 1943, Novel Device Regulatory Relief Act.
H.R. 3230, Keeping America Competitive through Harmonization Act.
H.R. 3205, FDA Renewing Efficiency from Outside Review Management Act.
H.R. 3211, Humanitarian Device Reform Act.
H.R. 3208, Patients Come First Act.
H.R. 3206, Cultivating Scientific Experts to Foster Innovation Act.
H.R. 3214, Food and Drug Administration Mission Reform Act.
H.R. 3207, Modernizing Laboratory Test Standards for Patients Act.
H.R. 3204, Guidance Accountability and Transparency Act.
S. 1700, The Medical Device Regulatory Improvement Act.
S. 1865, The Patient Access to Medical Innovation Act.
S. 1972, A bill to amend the Food and Drug Administrations mission.
S. 1995, A bill to enhance Food and Drug Administration oversight of medical device recalls, to provide for the conditional clearance of certain medical devices, and for other purposes.
CMS coverage for transcutaneous electrical nerve stimulation for lower back pain
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
International taxation on direct foreign investment.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
FY 2013 President's Budget
H. Con. Res. 112, Establishing the budget for the United States Government for fiscal year 2013 and setting forth appropriate budgetary levels for fiscal years 2014 through 2022.
Health care budget issues, fiscal year 2013 appropriations.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, PODESTA GROUP, INC. lobbied for Covidien , earning $60,000. The report was filed on July 20, 2012.
Original Filing: 300496162.xml
Lobbying Issues
Issues involving controlled substances and pain and addiction drugs.
Issues related to acetaminophen.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patient Protection and Affordable Care Act implementation.
S. 99, American Medical Isotopes Production Act of 2011; issues related to nuclear medicine.
FDA approval process/510(k).
Medical device tax.H.R. 3209, Premarket Predictability Act.
H.R. 3203 / S. 1943, Novel Device Regulatory Relief Act.
H.R. 3230, Keeping America Competitive through Harmonization Act.
H.R. 3205, FDA Renewing Efficiency from Outside Review Management Act.
H.R. 3211, Humanitarian Device Reform Act.
H.R. 3208, Patients Come First Act.
H.R. 3206, Cultivating Scientific Experts to Foster Innovation Act.
H.R. 3214, Food and Drug Administration Mission Reform Act.
H.R. 3207, Modernizing Laboratory Test Standards for Patients Act.
H.R. 3204, Guidance Accountability and Transparency Act.
S. 1700, The Medical Device Regulatory Improvement Act.
S. 1865, The Patient Access to Medical Innovation Act.
S. 1972, A bill to amend the Food and Drug Administrations mission.
S. 1995, A bill to enhance Food and Drug Administration oversight of medical device recalls, to provide for the conditional clearance of certain medical devices, and for other purposes.
CMS coverage for transcutaneous electrical nerve stimulation for lower back pain
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
International taxation on direct foreign investment.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
FY 2013 President's Budget
H. Con. Res. 112, Establishing the budget for the United States Government for fiscal year 2013 and setting forth appropriate budgetary levels for fiscal years 2014 through 2022.
Health care budget issues, fiscal year 2013 appropriations.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, PODESTA GROUP, INC. lobbied for Covidien , earning $50,000. The report was filed on April 20, 2012.
Original Filing: 300475223.xml
Lobbying Issues
Issues involving controlled substances and pain and addiction drugs.
Issues related to acetaminophen.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patient Protection and Affordable Care Act implementation.
S. 99, American Medical Isotopes Production Act of 2011; issues related to nuclear medicine.
FDA approval process/510(k).
Medical device tax.H.R. 3209, Premarket Predictability Act.
H.R. 3203 / S. 1943, Novel Device Regulatory Relief Act.
H.R. 3230, Keeping America Competitive through Harmonization Act.
H.R. 3205, FDA Renewing Efficiency from Outside Review Management Act.
H.R. 3211, Humanitarian Device Reform Act.
H.R. 3208, Patients Come First Act.
H.R. 3206, Cultivating Scientific Experts to Foster Innovation Act.
H.R. 3214, Food and Drug Administration Mission Reform Act.
H.R. 3207, Modernizing Laboratory Test Standards for Patients Act.
H.R. 3204, Guidance Accountability and Transparency Act.
S. 1700, The Medical Device Regulatory Improvement Act.
S. 1865, The Patient Access to Medical Innovation Act.
S. 1972, A bill to amend the Food and Drug Administrations mission.
S. 1995, A bill to enhance Food and Drug Administration oversight of medical device recalls, to provide for the conditional clearance of certain medical devices, and for other purposes.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
International taxation on direct foreign investment.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
FY 2013 President's Budget
H. Con. Res. 112, Establishing the budget for the United States Government for fiscal year 2013 and setting forth appropriate budgetary levels for fiscal years 2014 through 2022.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, PODESTA GROUP, INC. lobbied for Covidien , earning $50,000. The report was filed on Jan. 20, 2012.
Original Filing: 300449823.xml
Lobbying Issues
Issues involving controlled substances and pain and addiction drugs.
Issues related to acetaminophen.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patient Protection and Affordable Care Act implementation.
S. 99, American Medical Isotopes Production Act of 2011; issues related to nuclear medicine.
FDA approval process/510(k).
Medical device tax.H.R. 3209, Premarket Predictability Act.
H.R. 3203 / S. 1943, Novel Device Regulatory Relief Act.
H.R. 3230, Keeping America Competitive through Harmonization Act.
H.R. 3205, FDA Renewing Efficiency from Outside Review Management Act.
H.R. 3211, Humanitarian Device Reform Act.
H.R. 3208, Patients Come First Act.
H.R. 3206, Cultivating Scientific Experts to Foster Innovation Act.
H.R. 3214, Food and Drug Administration Mission Reform Act.
H.R. 3207, Modernizing Laboratory Test Standards for Patients Act.
H.R. 3204, Guidance Accountability and Transparency Act.
S. 1700, The Medical Device Regulatory Improvement Act.
S. 1865, The Patient Access to Medical Innovation Act.
S. 1972, A bill to amend the Food and Drug Administrations mission.
S. 1995, A bill to enhance Food and Drug Administration oversight of medical device recalls, to provide for the conditional clearance of certain medical devices, and for other purposes.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
International taxation on direct foreign investment.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 2055, Consolidated Appropriations Act, 2012.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Pub. L. 112-29, Leahy-Smith America Invents Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2011
In Q3, PODESTA GROUP, INC. lobbied for Covidien , earning $50,000. The report was filed on Oct. 20, 2011.
Original Filing: 300429577.xml
Lobbying Issues
Issues involving controlled substances and pain and addiction drugs.
Issues related to acetaminophen.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patient Protection and Affordable Care Act implementation.
S. 99, American Medical Isotopes Production Act of 2011; issues related to nuclear medicine.
FDA approval process/510(k).
Medical device tax.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1249 / S. 23, America Invents Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
International taxation on direct foreign investment.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
FY 2012 appropriations legislation.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, PODESTA GROUP, INC. lobbied for Covidien , earning $50,000. The report was filed on July 20, 2011.
Original Filing: 300405544.xml
Lobbying Issues
Issues involving controlled substances and pain and addiction drugs generally.
Issues related to acetaminophen.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Patient Protection and Affordable Care Act implementation.
S. 99, American Medical Isotopes Production Act of 2011; issues related to nuclear medicine.
FDA approval process/510(k).
Medical device tax.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1249 / S. 23, America Invents Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
International taxation on direct foreign investment.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
FY 2011 and FY 2012 Appropriations legislation.
Debt Ceiling Legislation.
Agencies Lobbied
U.S. Senate
1st Quarter, 2011
In Q1, PODESTA GROUP, INC. lobbied for Covidien , earning $50,000. The report was filed on April 19, 2011.
Original Filing: 300372803.xml
Lobbying Issues
Issues involving controlled substances and pain and addiction drugs generally.
Issues related to acetaminophen.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patient Protection and Affordable Care Act implementation.
S. 99, American Medical Isotopes Production Act of 2011; issues related to nuclear medicine.
FDA approval process/510(k).
Medical device tax.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1249 / S. 23, America Invents Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
International taxation on direct foreign investment.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
FY 2011 Appropriations legislation.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2010
In Q4, PODESTA GROUP, INC. lobbied for Covidien , earning $50,000. The report was filed on Jan. 20, 2011.
Original Filing: 300353375.xml
Lobbying Issues
Issues involving controlled substances and pain and addiction drugs generally
Issues related to acetaminophen
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1679 Kennedy Health Care Reform Bill
Senate Finance Committee Health Care Reform Bill
H.R. 3200 Tri-Committee Health Care Reform Bill
S. 1213, H.R. 2502 Comparative Effectiveness Research S. 1142 - Informed Health Care Decision Making Act
H.R. 3276 - Nuclear Medicine and Research Legislation
Medical Device Tax
H.R. 3590 - Patient Protection and Affordable Care Act implementation
H.R. 4872 - Health Care and Education Reconciliation Act of 2010 implementation
H.R. 4956 - Stop Oxy Abuse Act of 2010
Issues related to 510(k) changes
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1260 Patent Reform Act of 2009
S. 515 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
International tax on foreign direct investment.
H.R. 1265, Stop Tax Haven Abuse Act
S. 506, Stop Tax Haven Abuse Act
H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
FY11 Appropriations legislation
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
In Q3, PODESTA GROUP, INC. lobbied for Covidien , earning $50,000. The report was filed on Oct. 18, 2010.
Original Filing: 300316907.xml
Lobbying Issues
Issues involving controlled substances and pain and addiction drugs generally
Issues related to acetaminophen
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1679 Kennedy Health Care Reform Bill
Senate Finance Committee Health Care Reform Bill
H.R. 3200 Tri-Committee Health Care Reform Bill
S. 1213, H.R. 2502 Comparative Effectiveness Research S. 1142 - Informed Health Care Decision Making Act
H.R. 3276 - Nuclear Medicine and Research Legislation
Medical Device Tax
H.R. 3590 - Patient Protection and Affordable Care Act
H.R. 4872 - Health Care and Education Reconciliation Act of 2010
H.R. 4956 - Stop Oxy Abuse Act of 2010
Issues related to 510(k) changes
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1260 Patent Reform Act of 2009
S. 515 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
International tax on foreign direct investment.
H.R. 1265, Stop Tax Haven Abuse Act
S. 506, Stop Tax Haven Abuse Act
H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2010
In Q2, PODESTA GROUP, INC. lobbied for Covidien , earning $70,000. The report was filed on July 20, 2010.
Original Filing: 300300734.xml
Lobbying Issues
Issues involving controlled substances and pain and addiction drugs generally
Issues related to acetaminophen
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1679 Kennedy Health Care Reform Bill
Senate Finance Committee Health Care Reform Bill
H.R. 3200 Tri-Committee Health Care Reform Bill
S. 1213, H.R. 2502 Comparative Effectiveness Research S. 1142 - Informed Health Care Decision Making Act
H.R. 3276 - Nuclear Medicine and Research Legislation
Medical Device Tax
H.R. 3590 - Patient Protection and Affordable Care Act
H.R. 4872 - Health Care and Education Reconciliation Act of 2010
H.R. 4956 - Stop Oxy Abuse Act of 2010
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1260 Patent Reform Act of 2009
S. 515 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
International tax on foreign direct investment.
H.R. 1265, Stop Tax Haven Abuse Act
S. 506, Stop Tax Haven Abuse Act
H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2010
In Q1, PODESTA GROUP, INC. lobbied for Covidien , earning $70,000. The report was filed on April 20, 2010.
Original Filing: 300272883.xml
Lobbying Issues
Issues Involving Controlled Substances and Pain and Addiction Drugs Generally
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 301 Physician Payments Sunshine Act of 2009
S. 1213, H.R. 2502 Comparative Effectiveness Research
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1679 Kennedy Health Care Reform Bill
Senate Finance Committee Health Care Reform Bill
H.R. 3200 Tri-Committee Health Care Reform Bill
S. 1213, H.R. 2502 Comparative Effectiveness Research S. 1142 - Informed Health Care Decision Making Act
H.R. 3276 - Nuclear Medicine and Research Legislation
Medical Device Safety Act of 2009
Medical Device Tax
Bariatric Surgery
H.R. 3590 - Patient Protection and Affordable Care Act
H.R. 4872 - Health Care and Education Reconciliation Act of 2010
H.R. 1191/S.1336 - Safe Drug Disposal Act of 2009
H.R. 4956 - Stop Oxy Abuse Act of 2010
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1260 Patent Reform Act of 2009
S. 515 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
International tax on foreign direct investment.
H..R. 1265, Stop Tax Haven Abuse Act
S. 506, Stop Tax Haven Abuse Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 1 American Recovery and Reinvestment Act of 2009
S. Con. Res. 13
H. Con. Res. 85
H.R. 1105 Omnibus Appropriations Act, 2009 H.R. 2346, S. 1054 Supplemental Appropriations Bill, H1N1 Pandemic H.R. 23
Budget Requirements 2010
Financial Services Appropriations Bill
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2009
In Q4, PODESTA GROUP, INC. lobbied for Covidien , earning $70,000. The report was filed on Jan. 20, 2010.
Original Filing: 300248135.xml
Lobbying Issues
Issues Involving Controlled Substances and Pain and Addiction Drugs Generally
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 301 Physician Payments Sunshine Act of 2009
S. 1213, H.R. 2502 Comparative Effectiveness Research
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1679 Kennedy Health Care Reform Bill
Senate Finance Committee Health Care Reform Bill
H.R. 3200 Tri-Committee Health Care Reform Bill
S. 1213, H.R. 2502 Comparative Effectiveness Research S. 1142 Informed Health Care Decision Making Act
H.R. 3276, Nuclear Medicine and Research Legislation
Medical Device Safety Act of 2009
Medical Device Tax
Bariatric Surgery
H.R. 3590, Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1260 Patent Reform Act of 2009
S. 515 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
International tax on foreign direct investment.
H..R. 1265, Stop Tax Haven Abuse Act
S. 506, Stop Tax Haven Abuse Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 1 American Recovery and Reinvestment Act of 2009
S. Con. Res. 13
H. Con. Res. 85
H.R. 1105 Omnibus Appropriations Act, 2009 H.R. 2346, S. 1054 Supplemental Appropriations Bill, H1N1 Pandemic H.R. 23
Budget Requirements 2010
Financial Services Appropriations Bill
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2009
In Q3, PODESTA GROUP, INC. lobbied for Covidien , earning $70,000. The report was filed on Oct. 20, 2009.
Original Filing: 300216057.xml
Lobbying Issues
Issues Involving Controlled Substances and Pain and Addiction Drugs Generally
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 301 Physician Payments Sunshine Act of 2009
S. 1213, H.R. 2502 Comparative Effectiveness Research
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1679 Kennedy Health Care Reform Bill
Senate Finance Committee Health Care Reform Bill
H.R. 3200 Tri-Committee Health Care Reform Bill
S. 1213, H.R. 2502 Comparative Effectiveness Research S. 1142 Informed Health Care Decision Making Act
H.R. 3276 Nuclear Medicine and Research Legislation
Medical Device Safety Act of 2009
Medical Device Tax
Bariatric Surgery
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1260 Patent Reform Act of 2009
S. 515 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
International tax on foreign direct investment.
H..R. 1265, Stop Tax Haven Abuse Act
S. 506, Stop Tax Haven Abuse Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 1 American Recovery and Reinvestment Act of 2009
S. Con. Res. 13
H. Con. Res. 85
H.R. 1105 Omnibus Appropriations Act, 2009 H.R. 2346, S. 1054 Supplemental Appropriations Bill, H1N1 Pandemic H.R. 23
Budget Requirements 2010
Financial Services Appropriations Bill
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2009
In Q2, PODESTA GROUP, INC. lobbied for Covidien , earning $60,000. The report was filed on July 20, 2009.
Original Filing: 300191208.xml
Lobbying Issues
Issues Involving Controlled Substances and Pain and Addiction Drugs Generally
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 301 Physician Payments Sunshine Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Research on Bariatric Surgery
Kennedy Health Care Reform Bill
Baucus Health Care Reform Bill
Tri-Caucus Health Care Reform BillHouse Health Care Reform Bill
Nuclear Medicine and Research Legislation
Comparative Effectiveness Research Legislation; HELU/LEU
Medical Device Safety Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1260 Patent Reform Act of 2009
S. 515 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
International tax on foreign direct investment.
H..R. 1265, Stop Tax Haven Abuse Act
S. 506, Stop Tax Haven Abuse Act
Budget Requirements 2010Financial Services Appropriations Bill
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 1 American Recovery and Reinvestment Act of 2009
S. Con. Res. 13
H. Con. Res. 85
H.R. 1105 Omnibus Appropriations Act, 2009Supplemental Appropriations Bill, H1N1 Pandemic
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2009
In Q1, PODESTA GROUP, INC. lobbied for Covidien , earning $60,000. The report was filed on April 20, 2009.
Original Filing: 300165279.xml
Lobbying Issues
Issues Involving Controlled Substances and Pain and Addiction Drugs Generally
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 301 Physician Payments Sunshine Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Research on Bariatric Surgery
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1260 Patent Reform Act of 2009
S. 515 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H..R. 1265, Stop Tax Haven Abuse Act
S. 506, Stop Tax Haven Abuse Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 1 American Recovery and Reinvestment Act of 2009
S. Con. Res. 13
H. Con. Res. 85
H.R. 1105 Omnibus Appropriations Act, 2009
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2008
In Q4, PODESTA GROUP, INC. lobbied for Covidien , earning $30,000. The report was filed on Jan. 21, 2009.
Original Filing: 300128603.xml
Lobbying Issues
Average Manufacturer Price (AMP) changes
H. R. 3140, Saving Our Community Pharmacies Act
Issues Involving Controlled Substances and Pain and Addiction Drugs Generally
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. R. 1424, Paul Wellstone Mental Health and Addiction Equity Act, Sec. 105, Medicaid Drug Rebate
H. R. 3162, Children's Health and Medicare Protection Act of 2007
H. R. 5605, Physician Payments Sunshine Act of 2008
S. 2029, Physician Payments Sunshine Act of 2007S. 2221, Transparency in Medicare Device Pricing Act
S. 3118, Preserving Access to Medicare Act of 2008, Sec. 142
H.R. 6252, Medicare DMEPOS Competitive Acquisition Reform Act of 2008
S. 3144, Medicare DMEPOS Competitive Acquisition Reform Act of 2008
Medicare Coverage of Bariatric Surgery
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 6381, Medical Device Safety Act
H.R. 6151, Responsibility in Drug and Device Advertising Act of 2008
H.R. 2193, Animal Protection Accountability Improvement Act
Research on Bariatric Surgery
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 1908 Patent Reform Act of 2007
S 1145 Patent Reform Act of 2007
S. 3600, Patent Reform Act of 2008, entire bill
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R.6275, Alternative Minimum Tax Relief Act of 2008
FY 2009 Administration Budget
H.R.7005, Alternative Minimum Tax Relief Act of 2008
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
FY2009 House Financial Services Appropriations.
S.3260 FY09 Senate Finacial Services Appropriations
FY2009 House Defense Appropriations
FY2009 Senate Defense Appropriations
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2008
In Q3, PODESTA GROUP, INC. lobbied for Covidien , earning $30,000. The report was filed on Oct. 20, 2008.
Original Filing: 300101714.xml
Lobbying Issues
Average Manufacturer Price (AMP) changes
H. R. 3140, Saving Our Community Pharmacies Act
Issues Involving Controlled Substances and Pain and Addiction Drugs Generally
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. R. 1424, Paul Wellstone Mental Health and Addiction Equity Act, Sec. 105, Medicaid Drug Rebate
H. R. 3162, Children's Health and Medicare Protection Act of 2007
H. R. 5605, Physician Payments Sunshine Act of 2008
S. 2029, Physician Payments Sunshine Act of 2007S. 2221, Transparency in Medicare Device Pricing Act
S. 3118, Preserving Access to Medicare Act of 2008, Sec. 142
S. 3101, Medicare Improvements for Patients and Providers Act of 2008, Sec. 144
H.R. 6331, Medicare Improvements for Patients and Providers Act of 2008, Sec 154
H.R. 6252, Medicare DMEPOS Competitive Acquisition Reform Act of 2008
S. 3144, Medicare DMEPOS Competitive Acquisition Reform Act of 2008
Medicare Coverage of Bariatric Surgery
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 6381, Medical Device Safety Act
H.R. 6151, Responsibility in Drug and Device Advertising Act of 2008
H.R. 2193, Animal Protection Accountability Improvement Act
Research on Bariatric Surgery
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 1908 Patent Reform Act of 2007
S 1145 Patent Reform Act of 2007
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R.6275, Alternative Minimum Tax Relief Act of 2008
FY 2009 Administration Budget
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
FY2009 House Financial Services Appropriations.
S.3260 FY09 Senate Finacial Services Appropriations
FY2009 House Defense Appropriations
FY2009 Senate Defense Appropriations
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2008
In Q2, PODESTA GROUP, INC. lobbied for Covidien , earning $60,000. The report was filed on July 21, 2008.
Original Filing: 300082664.xml
Lobbying Issues
Average Manufacturer Price (AMP) changes
H. R. 3140, Saving Our Community Pharmacies Act
H. R. 3700, Fair Medicaid Drug Payment Act
S. 1951, Fair Medicaid Drug Payment ActMethadone Regulation
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. R. 1424, Paul Wellstone Mental Health and Addiction Equity Act, Sec. 105, Medicaid Drug Rebate
H. R. 3162, Children's Health and Medicare Protection Act of 2007
H. R. 5605, Physician Payments Sunshine Act of 2008
S. 2029, Physician Payments Sunshine Act of 2007S. 2221, Transparency in Medicare Device Pricing Act
S. 3118, Preserving Access to Medicare Act of 2008, Sec. 142
S. 3101, Medicare Improvements for Patients and Providers Act of 2008, Sec. 144
H.R. 6331, Medicare Improvements for Patients and Providers Act of 2008, Sec 154
H.R. 6252, Medicare DMEPOS Competitive Acquisition Reform Act of 2008
S. 3144, Medicare DMEPOS Competitive Acquisition Reform Act of 2008
Medicare Coverage of Bariatric Surgery
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2419, Farm, Nutrition and Bioenergy Act, Sec. 11316, Medical Device Prohibitions
Research on Bariatric Surgery
Preemption for Medical Devices
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 1908 Patent Reform Act of 2007
S 1145 Patent Reform Act of 2007
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
International Tax on foreign direct investment
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
FY2009 House Financial Services Appropriations.
S.3260 FY09 Senate Finacial Services Appropriations
FY2009 House Defense Appropriations
FY2009 Senate Defense Appropriations
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2008
In Q1, PODESTA GROUP, INC. lobbied for Covidien , earning $60,000. The report was filed on April 21, 2008.
Original Filing: 300055491.xml
Lobbying Issues
Average Manufacturer Price (AMP) changes
H. R. 3140, Saving Our Community Pharmacies Act
H. R. 3700, Fair Medicaid Drug Payment Act
S. 1951, Fair Medicaid Drug Payment Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. R. 1424, Paul Wellstone Mental Health and Addiction Equity Act, Sec. 105, Medicaid Drug Rebate
H. R. 3162, Children's Health and Medicare Protection Act of 2007
H. R. 5605, Physician Payments Sunshine Act of 2008
S. 2029, Physician Payments Sunshine Act of 2007S. 2221, Transparency in Medicare Device Pricing Act
Senate legislation to update physician payments, oxygen provisions
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2419, Farm, Nutrition and Bioenergy Act, Sec. 11316, Medical Device Prohibitions
Agencies Lobbied
U.S. House of Representatives
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...